Kalaris Therapeutics, Inc. (KLRS), a biopharmaceutical company, Monday announced that it has appointed Matthew Gall, as its chief financial officer.
Most recently, Gall was the finance chief of iTeos Therapeutics, and prior to iTeos he held positions at Sarepta Therapeutics, Celgene Corporation, and Gilead Sciences across the finance and business development functions.
In pre-market activity, Kalaris shares are trading at $5.45, up 8.35% on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.